» Articles » PMID: 35808839

Engineered Exosomes for Studies in Tumor Immunology

Overview
Journal Immunol Rev
Date 2022 Jul 9
PMID 35808839
Authors
Affiliations
Soon will be listed here.
Abstract

Exosomes are a type of extracellular vesicle (EV) with diameters of 30-150 nm secreted by most of the cells into the extracellular spaces and can alter the microenvironment through cell-to-cell interactions by fusion with the plasma membrane and subsequent endocytosis and release of the cargo. Because of their biocompatibility, low toxicity and immunogenicity, permeability (even through the blood-brain barrier (BBB)), stability in biological fluids, and ability to accumulate in the lesions with higher specificity, investigators have started making designer's exosomes or engineered exosomes to carry biologically active protein on the surface or inside the exosomes as well as using exosomes to carry drugs, micro RNA, and other products to the site of interest. In this review, we have discussed biogenesis, markers, and contents of various exosomes including exosomes of immune cells. We have also discussed the current methods of making engineered and designer's exosomes as well as the use of engineered exosomes targeting different immune cells in the tumors, stroke, as well as at peripheral blood. Genetic engineering and customizing exosomes create an unlimited opportunity to use in diagnosis and treatment. Very little use has been discovered, and we are far away to reach its limits.

Citing Articles

Key developments and hotspots of exosomes in Alzheimer's disease: a bibliometric study spanning 2003 to 2023.

Liu S, Geng D Front Aging Neurosci. 2024; 16:1377672.

PMID: 38752210 PMC: 11094344. DOI: 10.3389/fnagi.2024.1377672.


Research Advances of Engineered Exosomes as Drug Delivery Carrier.

Huang L, Wu E, Liao J, Wei Z, Wang J, Chen Z ACS Omega. 2023; 8(46):43374-43387.

PMID: 38027310 PMC: 10666244. DOI: 10.1021/acsomega.3c04479.


Applications and Research Advances in the Delivery of CRISPR/Cas9 Systems for the Treatment of Inherited Diseases.

Lu X, Zhang M, Li G, Zhang S, Zhang J, Fu X Int J Mol Sci. 2023; 24(17).

PMID: 37686009 PMC: 10487642. DOI: 10.3390/ijms241713202.


Comprehensive characterization of pyroptosis phenotypes with distinct tumor immune profiles in gastric cancer to aid immunotherapy.

Huang K, Lin Y, Qiu G, Wang S, Feng L, Zheng Z Aging (Albany NY). 2023; 15(16):8113-8136.

PMID: 37595258 PMC: 10497016. DOI: 10.18632/aging.204958.


Mesenchymal stem cells, as glioma exosomal immunosuppressive signal multipliers, enhance MDSCs immunosuppressive activity through the miR-21/SP1/DNMT1 positive feedback loop.

Qiu W, Guo Q, Guo X, Wang C, Li B, Qi Y J Nanobiotechnology. 2023; 21(1):233.

PMID: 37481646 PMC: 10362641. DOI: 10.1186/s12951-023-01997-x.


References
1.
Wang M, Zhou L, Yu F, Zhang Y, Li P, Wang K . The functional roles of exosomal long non-coding RNAs in cancer. Cell Mol Life Sci. 2019; 76(11):2059-2076. PMC: 11105177. DOI: 10.1007/s00018-019-03018-3. View

2.
Rana S, Yue S, Stadel D, Zoller M . Toward tailored exosomes: the exosomal tetraspanin web contributes to target cell selection. Int J Biochem Cell Biol. 2012; 44(9):1574-84. DOI: 10.1016/j.biocel.2012.06.018. View

3.
Oksvold M, Neurauter A, Pedersen K . Magnetic bead-based isolation of exosomes. Methods Mol Biol. 2014; 1218:465-81. DOI: 10.1007/978-1-4939-1538-5_27. View

4.
Gauvreau M, Cote M, Bourgeois-Daigneault M, Rivard L, Xiu F, Brunet A . Sorting of MHC class II molecules into exosomes through a ubiquitin-independent pathway. Traffic. 2009; 10(10):1518-27. DOI: 10.1111/j.1600-0854.2009.00948.x. View

5.
Xia Y, He X, Xu X, Tian B, An Y, Chen F . Exosomes derived from M0, M1 and M2 macrophages exert distinct influences on the proliferation and differentiation of mesenchymal stem cells. PeerJ. 2020; 8:e8970. PMC: 7185029. DOI: 10.7717/peerj.8970. View